My watch list  

Atriva Therapeutics GmbH

First-in-class inhibitors against respiratory viral infections

ATRIVA aims to develop new antiviral therapies against different respiratory viral infections. Founded in 2015, ATRIVA attracted seasoned experts in virology and drug development to form a unique venture targeting the fast and successful validation of a novel approach to fight infectious diseases Inhibitors of certain cellular signaling pathways, the so called “MEK-Inhibitors”, have shown a superior antiviral activity by blocking viral replication. This creates an unprecedented potential for truly efficacious and safe therapeutics against numerous viral infections.

ATRIVA closed a seed financing of € 3 Mn in late 2016. The proceeds of this allows the company to reach clinical development with its lead project ATR-002 for influenza in high-risk patients. We invite you to explore our approach and pipeline presented on this website and encourage you to contact us directly.


Science4Life Venture Cup 2016

High-Tech Gründerfonds

More about Atriva Therapeutics
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE